HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients. Issue 9 (January 2014)

• Record Type: Journal Article
• Authors: Furukawa, Hiroshi; Oka, Shomi; Shimada, Kota; Sugii, Shoji; Hashimoto, Atsushi; Komiya, Akiko; Fukui, Naoshi; Miyashita, Taiichiro; Migita, Kiyoshi; Suda, Akiko; Nagaoka, Shouhei; Tsuchiya, Naoyuki; Tohma, Shigeto
• Is Part Of: Biomarker insights. Volume 2015:Issue 9(2014)
• Publication Date: 2014-01
• Subjects: bucillamine -- drug-induced proteinuria -- HLA-DRB1*08:02 -- rheumatoid arthritis -- disease-modifying anti-rheumatic drugs; Biochemical markers -- Periodicals; 572.43
• DOI: 10.4137/BMI.S13654
• Languages: English
• ISSNs: 1177-2719

Abstract

Background: Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated with d-penicillamine, gold salts, or bucillamine (Buc), and represents a drug hypersensitivity reaction. Striking associations of human leukocyte antigen (HLA) alleles with adverse reactions have recently been reported for many drugs. Methods: We investigated the association of HLA class II with Buc-induced proteinuria (BI-Pro) in 485 Japanese RA patients treated with Buc, of whom 25 had developed BI-Pro. Results and Conclusion: This preliminary study showed a highly significant association of DRB1*08:02 with BI-Pro ( P = 1.09 × 10 −6, corrected P [ Pc ] = 1.96 × 10 −5, odds ratio [OR] 25.17, 95% confidence interval [CI] 7.98-79.38). DQB1*04:02 was also significantly associated with increased risk of BI-Pro ( P = 2.44 × 10 −5, Pc = 2.69 × 10 −4, OR 10.35, 95%CI 3.99–26.83). These findings provide useful information for promoting personalized medicine for RA.